Suppr超能文献

颅内血肿液化的实验研究:溶栓剂组织型纤溶酶原激活剂(t-PA)及其联合应用的效用

[Experimental study on liquefaction of intracranial hematoma: usefulness of tissue-plasminogen activator (t-PA), a hematolytic agent, and its combination].

作者信息

Ebina K, Okabe S, Manabe H, Iwabuchi T

机构信息

Department of Neurosurgery, Hirosaki University School of Medicine, Aomori, Japan.

出版信息

No Shinkei Geka. 1990 Oct;18(10):927-34.

PMID:2122269
Abstract

In stereotaxic aspiration of intracerebral hematoma and extensive removal, or cisternal drainage for subarachnoid hematoma, rapid and safe liquefaction and removal of clots are important and urgent measures to be taken. We performed a pharmacological experimental study on the efficacy, administration method, and toxicity of various hematolytic agents, especially tissue-Plasminogen Activator (t-PA). The following findings were obtained. 1) The amount, hardness, and histological findings concerning the remaining hematoma differed markedly according to which hematolytic agents were used. 2) The local effects of each hematolytic agent continued for about 4-8 hours but markedly decreased thereafter. 3) The hematolysis rate following single administration (6 hours after the blood collection) was 88.9% with t-PA + Elase (Fibrinolysin + Deoxyribonuclease), 85.4% with t-PA, 84.6% with t-PA + Urokinase, 80.2% with t-PA + Urokinase + Elase, 27.55 with Elase + Urokinase, 24.6% with Elase + Urokinase + Heparin, 17.2% with Heparin + Urokinase, 16.4% with Urokinase, 13.2% with Elase + Heparin, 12.6% with Elase, 9.3% with Heparin, and 10.1% with the control (Saline). Locally administered t-PA had remarkably greater hematolytic effects than Urokinase on the hematoma (p less than 0.001). 4) The hematolysis rate after 24 hours of repeated administration of small doses at 8-hour intervals was 100% with t-PA + Urokinase + Elase, 94.2% with t-PA, 93.8% with t-PA + Urokinase, 50.9% with Elase + Urokinase, 46.6% with Elase + Urokinase + Heparin, 33.7% with Urokinase, and 4.8% with the control.(ABSTRACT TRUNCATED AT 250 WORDS)

摘要

在脑内血肿的立体定向抽吸及广泛清除,或蛛网膜下腔血肿的脑池引流中,快速且安全地液化和清除血凝块是需要采取的重要且紧急的措施。我们对各种溶血栓药物,尤其是组织型纤溶酶原激活剂(t-PA)的疗效、给药方法及毒性进行了药理学实验研究。获得了以下结果。1)根据所使用的溶血栓药物不同,剩余血肿的量、硬度及组织学表现有显著差异。2)每种溶血栓药物的局部作用持续约4 - 8小时,但此后显著减弱。3)单次给药(采血后6小时)后的溶血率,t-PA + 胰弹性蛋白酶(纤维蛋白溶酶 + 脱氧核糖核酸酶)为88.9%,t-PA为85.4%,t-PA + 尿激酶为84.6%,t-PA + 尿激酶 + 胰弹性蛋白酶为80.2%,胰弹性蛋白酶 + 尿激酶为27.5%,胰弹性蛋白酶 + 尿激酶 + 肝素为24.6%,肝素 + 尿激酶为17.2%,尿激酶为16.4%,胰弹性蛋白酶 + 肝素为13.2%,胰弹性蛋白酶为12.6%,肝素为9.3%,对照组(生理盐水)为10.1%。局部应用t-PA对血肿的溶血作用明显大于尿激酶(p小于0.001)。4)每隔8小时小剂量重复给药24小时后的溶血率,t-PA + 尿激酶 + 胰弹性蛋白酶为100%,t-PA为94.2%,t-PA + 尿激酶为93.8%,胰弹性蛋白酶 + 尿激酶为50.9%,胰弹性蛋白酶 + 尿激酶 + 肝素为46.6%,尿激酶为33.7%,对照组为4.8%。(摘要截短至250字)

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验